COVID-19 and the Use of Natural Products

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
S. Mandal
{"title":"COVID-19 and the Use of Natural Products","authors":"S. Mandal","doi":"10.22127/rjp.2021.287851.1702","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by a new variant of coronavirus which has already spread in more than 150 countries and gained global attention. The absence of efficient and effective medicines towards this disease has indeed aggravated the situation [1]. Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) was an extremely contagious virus that caused serious disease and death. This virus has been found to cause human respiratory, enteric, and neurological disorders. This is one of the seven known coronavirus strains, found to inflict human infection and the latest outbreak of coronavirus in 2019 was triggered by the strain called SARS-CoV-2. Other strains include HCoV-NL-63, HCoV-229E, HCoV-OC43, HCoV-HKu1, MERS-CoV, etc. [2,3]. Coronavirus 2019 has quickly spread to the international community originating from Wuhan city, Hubei in China [4]. The exponential growth of this new coronavirus strain has already imposed strict four-tier guidelines in UK. In September 2019, it was first observed in UK. In mid-December, this amounted to almost two-thirds of population in UK [5]. On 30th January 2020, it was first reported in India through a student from Wuhan [13]. The world health organization (WHO) declared corona virus outbreak as a global pandemic on 11th March 2020 [12]. \nConsidering the structure, there are four key proteins included in the structural composition of coronaviruses. Those are Spike (S), Membrane (M), Envelope (E) and Nucleocapsid (N). Spike, a trimeric glycoprotein of CoV, establishes CoV variability and host tropism and also facilitates CoVs which bind to virus-cell membrane fusion and surface-specific receptor [6]. SARS-CoV-2 enters cells through this structural spike protein (S), which bind to the angiotensin converting enzyme-2 (ACE-2) receptor. Host cell receptors and endosomes are used by the spike proteins (S) to enter the cells after receptor binding. The transmembrane protease serine 2 (TMPRSS2), a host type 2 transmembrane serine protease, enables cell entry through the S-protein. The viral polyproteins which code for replicase transcriptase complex are synthesized once within the cell. SARS-CoV-2 synthesizes RNA through RNA dependent RNA polymerase enzyme. Structural proteins are generated, resulting in the formation and discharge of viral particles. The forthcoming drug treatments are included in these stages of the viral life cycle. Non-structural proteins like RNA dependent RNA polymerase, papain proteases, 3-chymotrypsin-like proteases which establish homologies with the other novel coronaviruses, are considered as promising medication targets. Additional drug targets include entry of virus and immune control [7]. At the time of sneezing and coughing, infection can transmit by enormous droplets through the symptomatic individuals. The infection may also occur in asymptomatic people before the symptoms start. In comparison to throat, studies indicate higher nasal cavity viral loads, with no viral load difference between asymptomatic and symptomatic individuals. The infection comes from the inhalation or contact with surfaces infected with such droplets, accompanied by the touch of the nose, eyes and mouth [4]. \nNatural products have been found to play significant role throughout the decades in prevention and treatment of several diseases. The essential oils and extracts derived from plants and animals are regarded as commendable source of biologically active molecules. A variety of natural products have already been reported as antiviral against enterovirus, hepatitis B, dengue, Influenza virus, coronavirus, and human immunodeficiency virus [8]. \nA research done by Wen et al. in 2007 examined that twenty-two terpenoids and lignoids could suppress SARS-CoV replication in African Green Monkey Kidney (Vero) E6 cells. The cytotoxicity of the metabolites against Vero E6 cells has been assessed and the inhibitory activity has been examined. The most active secondary metabolites have been reported as betulonic acid, savinin, ferruginol, 3s,12-diacetoxyabieta-6, 8-11,13-tetraene and 7s-hydroxydeoxycryptojaponol, respectively. These compounds were known as powerful effective inhibitors of viral replication at concentrations of 0.63, 1.13, 1.47, 1.39, 1.57 and 1.15 µM respectively [2]. Emodin, an anthraquinone from Rheum officinale Baill, and Reynoutria multiflora (Thunb.) Moldenkehas been used as anti-bacterial and anti-inflammatory agent. Ho et al. confirmed in 2007 that emodin inhibited the binding of S protein to ACE-2 and reduced infection of pseudo-typed S protein in cells of Vero E6. The dose-dependent interaction between S and ACE-2 was completely prevented by emodin with an IC50 of 200 μM, suggesting that it can be a therapeutic agent for SARS treatment [9]. Some of the popular natural immune boosters such as herbal medicines are useful in COVID-19 prevention. Herbal medicines include Glycyrrhiza glabra, Zingiber officinale, Echinacea spp., Nigella sativa, Hypericum perforatum, Allium sativum, Camellia sinensis. In addition, natural products play a significant role in the prevention of infection, especially in high-risk patients suffering from coronavirus infections [10]. \nLuo et al. stated that Atractylodis macrocephalae, Glycyrrhizae uralensis, Lonicerae japonica, Astragalus mongholicus, Saposhnikovia divaricata, Atractylodeslancea, Forsythia suspensa, Cyrtomium fortunei, Agastache rugosaetac were used in the prophylaxis of COVID-19 [11]. Inhibitory activity against SARS-CoV papain-like protease (PLpro) and SARS-CoV 3-chymotrypsin-like proteases (3CLpro) with IC50 values of 1.2 and 11.4 μM, respectively is reported from a chalcone named xanthoangelol E, which is isolated from the ethanolic leaf extract of Angelica keiskei [2]. \nThe outbreak of this new strain of coronavirus has challenged medical, economic, and public health infrastructure of many countries. The outbreaks of these kinds of viruses and pathogens are very much probable to continue in future. Natural products have a pivotal role in the prophylaxis or prevention of COVID-19. But there is no such evidence in the literature that it can also prevent the mutant strain of coronavirus. Therefore, efforts should be implemented to devise measures and investigate the utilization of natural products more precisely which can prevent such outbreaks of viruses in the future.","PeriodicalId":21088,"journal":{"name":"Research Journal of Pharmacognosy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmacognosy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22127/rjp.2021.287851.1702","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by a new variant of coronavirus which has already spread in more than 150 countries and gained global attention. The absence of efficient and effective medicines towards this disease has indeed aggravated the situation [1]. Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) was an extremely contagious virus that caused serious disease and death. This virus has been found to cause human respiratory, enteric, and neurological disorders. This is one of the seven known coronavirus strains, found to inflict human infection and the latest outbreak of coronavirus in 2019 was triggered by the strain called SARS-CoV-2. Other strains include HCoV-NL-63, HCoV-229E, HCoV-OC43, HCoV-HKu1, MERS-CoV, etc. [2,3]. Coronavirus 2019 has quickly spread to the international community originating from Wuhan city, Hubei in China [4]. The exponential growth of this new coronavirus strain has already imposed strict four-tier guidelines in UK. In September 2019, it was first observed in UK. In mid-December, this amounted to almost two-thirds of population in UK [5]. On 30th January 2020, it was first reported in India through a student from Wuhan [13]. The world health organization (WHO) declared corona virus outbreak as a global pandemic on 11th March 2020 [12]. Considering the structure, there are four key proteins included in the structural composition of coronaviruses. Those are Spike (S), Membrane (M), Envelope (E) and Nucleocapsid (N). Spike, a trimeric glycoprotein of CoV, establishes CoV variability and host tropism and also facilitates CoVs which bind to virus-cell membrane fusion and surface-specific receptor [6]. SARS-CoV-2 enters cells through this structural spike protein (S), which bind to the angiotensin converting enzyme-2 (ACE-2) receptor. Host cell receptors and endosomes are used by the spike proteins (S) to enter the cells after receptor binding. The transmembrane protease serine 2 (TMPRSS2), a host type 2 transmembrane serine protease, enables cell entry through the S-protein. The viral polyproteins which code for replicase transcriptase complex are synthesized once within the cell. SARS-CoV-2 synthesizes RNA through RNA dependent RNA polymerase enzyme. Structural proteins are generated, resulting in the formation and discharge of viral particles. The forthcoming drug treatments are included in these stages of the viral life cycle. Non-structural proteins like RNA dependent RNA polymerase, papain proteases, 3-chymotrypsin-like proteases which establish homologies with the other novel coronaviruses, are considered as promising medication targets. Additional drug targets include entry of virus and immune control [7]. At the time of sneezing and coughing, infection can transmit by enormous droplets through the symptomatic individuals. The infection may also occur in asymptomatic people before the symptoms start. In comparison to throat, studies indicate higher nasal cavity viral loads, with no viral load difference between asymptomatic and symptomatic individuals. The infection comes from the inhalation or contact with surfaces infected with such droplets, accompanied by the touch of the nose, eyes and mouth [4]. Natural products have been found to play significant role throughout the decades in prevention and treatment of several diseases. The essential oils and extracts derived from plants and animals are regarded as commendable source of biologically active molecules. A variety of natural products have already been reported as antiviral against enterovirus, hepatitis B, dengue, Influenza virus, coronavirus, and human immunodeficiency virus [8]. A research done by Wen et al. in 2007 examined that twenty-two terpenoids and lignoids could suppress SARS-CoV replication in African Green Monkey Kidney (Vero) E6 cells. The cytotoxicity of the metabolites against Vero E6 cells has been assessed and the inhibitory activity has been examined. The most active secondary metabolites have been reported as betulonic acid, savinin, ferruginol, 3s,12-diacetoxyabieta-6, 8-11,13-tetraene and 7s-hydroxydeoxycryptojaponol, respectively. These compounds were known as powerful effective inhibitors of viral replication at concentrations of 0.63, 1.13, 1.47, 1.39, 1.57 and 1.15 µM respectively [2]. Emodin, an anthraquinone from Rheum officinale Baill, and Reynoutria multiflora (Thunb.) Moldenkehas been used as anti-bacterial and anti-inflammatory agent. Ho et al. confirmed in 2007 that emodin inhibited the binding of S protein to ACE-2 and reduced infection of pseudo-typed S protein in cells of Vero E6. The dose-dependent interaction between S and ACE-2 was completely prevented by emodin with an IC50 of 200 μM, suggesting that it can be a therapeutic agent for SARS treatment [9]. Some of the popular natural immune boosters such as herbal medicines are useful in COVID-19 prevention. Herbal medicines include Glycyrrhiza glabra, Zingiber officinale, Echinacea spp., Nigella sativa, Hypericum perforatum, Allium sativum, Camellia sinensis. In addition, natural products play a significant role in the prevention of infection, especially in high-risk patients suffering from coronavirus infections [10]. Luo et al. stated that Atractylodis macrocephalae, Glycyrrhizae uralensis, Lonicerae japonica, Astragalus mongholicus, Saposhnikovia divaricata, Atractylodeslancea, Forsythia suspensa, Cyrtomium fortunei, Agastache rugosaetac were used in the prophylaxis of COVID-19 [11]. Inhibitory activity against SARS-CoV papain-like protease (PLpro) and SARS-CoV 3-chymotrypsin-like proteases (3CLpro) with IC50 values of 1.2 and 11.4 μM, respectively is reported from a chalcone named xanthoangelol E, which is isolated from the ethanolic leaf extract of Angelica keiskei [2]. The outbreak of this new strain of coronavirus has challenged medical, economic, and public health infrastructure of many countries. The outbreaks of these kinds of viruses and pathogens are very much probable to continue in future. Natural products have a pivotal role in the prophylaxis or prevention of COVID-19. But there is no such evidence in the literature that it can also prevent the mutant strain of coronavirus. Therefore, efforts should be implemented to devise measures and investigate the utilization of natural products more precisely which can prevent such outbreaks of viruses in the future.
新冠肺炎与天然产品的使用
2019冠状病毒病(新冠肺炎)是一种由新型冠状病毒引起的高度传染性疾病,已在150多个国家传播并引起全球关注。缺乏治疗这种疾病的有效药物确实加剧了这种情况[1]。严重急性呼吸系统综合征冠状病毒是一种传染性极强的病毒,可导致严重疾病和死亡。这种病毒已被发现会导致人类呼吸、肠道和神经系统疾病。这是已知的七种冠状病毒毒株之一,被发现会引起人类感染,2019年最新的冠状病毒爆发是由一种名为严重急性呼吸系统综合征冠状病毒2型的毒株引发的。其他菌株包括HCoV-NL-63、HCoV-229E、HCoV OC43、HCo病毒HKu1、MERS-CoV等[2,3]。2019冠状病毒已迅速传播到源自中国湖北省武汉市的国际社会[4]。这种新型冠状病毒株的指数级增长已经在英国实施了严格的四级指导方针。2019年9月,它首次在英国被观察到。12月中旬,这一数字几乎占英国人口的三分之二[5]。2020年1月30日,印度通过一名来自武汉的学生首次报道了这一消息[13]。世界卫生组织(世界卫生组织)于2020年3月11日宣布冠状病毒疫情为全球大流行[12]。从结构上看,冠状病毒的结构组成中包括四种关键蛋白质。它们是刺突(S)、膜(M)、包膜(E)和核衣壳(N)。Spike是冠状病毒的三聚体糖蛋白,建立了冠状病毒的变异性和宿主嗜性,也促进了冠状病毒与病毒细胞膜融合和表面特异性受体的结合[6]。严重急性呼吸系统综合征冠状病毒2型通过这种结构刺突蛋白(S)进入细胞,刺突蛋白与血管紧张素转换酶-2(ACE-2)受体结合。刺突蛋白(S)利用宿主细胞受体和内体在受体结合后进入细胞。跨膜蛋白酶丝氨酸2(TMPRSS2)是一种宿主2型跨膜丝氨酸蛋白酶,能够通过S蛋白进入细胞。编码复制酶-转录酶复合物的病毒多蛋白在细胞内合成一次。严重急性呼吸系统综合征冠状病毒2型通过RNA依赖性RNA聚合酶合成RNA。产生结构蛋白,导致病毒颗粒的形成和排出。即将到来的药物治疗包括在病毒生命周期的这些阶段。与其他新型冠状病毒建立同源性的非结构蛋白,如RNA依赖性RNA聚合酶、木瓜蛋白酶、3-糜蛋白酶样蛋白酶,被认为是有前景的药物靶点。其他药物靶点包括病毒进入和免疫控制[7]。在打喷嚏和咳嗽时,感染可以通过巨大的飞沫通过有症状的个体传播。在症状出现之前,无症状的人也可能出现感染。与喉咙相比,研究表明鼻腔病毒载量更高,无症状和有症状的个体之间没有病毒载量差异。感染源于吸入或接触被这种飞沫感染的表面,并伴有触摸鼻子、眼睛和嘴巴[4]。几十年来,人们发现天然产物在预防和治疗多种疾病方面发挥着重要作用。植物和动物的精油和提取物被认为是值得称赞的生物活性分子来源。多种天然产物已被报道为对肠道病毒、乙型肝炎、登革热、流感病毒、冠状病毒和人类免疫缺陷病毒的抗病毒药物[8]。温等人在2007年进行的一项研究表明,二十二种萜类化合物和木质素类化合物可以抑制非洲绿猴肾(Vero)E6细胞中严重急性呼吸系统综合征冠状病毒的复制。已经评估了代谢物对Vero E6细胞的细胞毒性,并检测了抑制活性。据报道,最具活性的次级代谢产物分别为桦木酸、savinin、Ferraginol、3s、12-二乙酰氧基abieta-6、8-11,13-四烯和7s-羟基脱氧隐日本烯醇。这些化合物被认为是病毒复制的强大有效抑制剂,浓度分别为0.63、1.13、1.47、1.39、1.57和1.15µM[2]。大黄中的蒽醌大黄素和多花Reynoutria(Thunb.)Moldenkeha被用作抗菌和抗炎剂。Ho等人在2007年证实,大黄素抑制了S蛋白与ACE-2的结合,并减少了Vero E6细胞中伪型S蛋白的感染。IC50为200μM的大黄素完全阻止了S和ACE-2之间的剂量依赖性相互作用,表明它可以作为SARS治疗的治疗剂[9]。一些流行的天然免疫增强剂,如草药,可用于预防新冠肺炎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research Journal of Pharmacognosy
Research Journal of Pharmacognosy PHARMACOLOGY & PHARMACY-
CiteScore
1.10
自引率
20.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信